|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2018. CA Cancer J Clin. 68:7–30. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ferlay J, Soerjomataram I, Dikshit R, Eser
S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer
incidence and mortality worldwide: Sources, methods and major
patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Jiang X, Tang H and Chen T: Epidemiology
of gynecologic cancers in China. J Gynecol Oncol. 29:e72018.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Wang H, Cheng X, Ye J, Xu X, Hong Y, Sui
L, You Z and Xie X: Distribution of human papilloma virus genotype
prevalence in invasive cervical carcinomas and precancerous lesions
in the Yangtze River Delta area, China. BMC Cancer. 18:4872018.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
de Sanjose S, Quint WG, Alemany L, Geraets
DT, Klaustermeier JE, Lloveras B, Tous S, Felix A, Bravo LE, Shin
HR, et al: Human papillomavirus genotype attribution in invasive
cervical cancer: A retrospective cross-sectional worldwide study.
Lancet Oncol. 11:1048–1056. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Depuydt CE, Beert J, Bosmans E and
Salembier G: Human Papillomavirus (HPV) virion induced cancer and
subfertility, two sides of the same coin. Facts Views Vis Obgyn.
8:211–222. 2016.PubMed/NCBI
|
|
7
|
Jiang E, Sun X, Kang H, Sun L, An W, Yao Y
and Hu X: Dehydrocostus lactone inhibits proliferation,
antiapoptosis, and invasion of cervical cancer cells through
PI3K/Akt signaling pathway. Int J Gynecol Cancer. 25:1179–1186.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Lee RC, Feinbaum RL and Ambros V: The C.
elegans heterochronic gene lin-4 encodes small RNAs with antisense
complementarity to lin-14. Cell. 75:843–854. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Ambros V: The functions of animal
micrornas. Nature. 431:350–355. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Romano G, Veneziano D, Acunzo M and Croce
CM: Small non-coding RNA and cancer. Carcinogenesis. 38:485–491.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Lorenzi L, Avila Cobos F, Decock A,
Everaert C, Helsmoortel H, Lefever S, Verboom K, Volders PJ,
Speleman F, Vandesompele J and Mestdagh P: Long non-coding RNA
expression profiling in cancer: Challenges and opportunities. Genes
Chromosomes Cancer. 2018 Nov 21;Doi: 10.1002/gcc.22709. (Epub ahead
of print). View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Di Leva G, Garofalo M and Croce CM:
MicroRNAs in cancer. Annu Rev Pathol. 9:287–314. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Soto D, Song C and McLaughlin-Drubin ME:
Epigenetic alterations in human papillomavirus-associated cancers.
Viruses. 9:E2482017. View
Article : Google Scholar : PubMed/NCBI
|
|
14
|
Eskander RN: The epigenetic landscape in
the treatment of gynecologic malignancies. Am Soc Clin Oncol Educ
Book. 480–487. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Pardini B, De Maria D, Francavilla A, Di
Gaetano C, Ronco G and Naccarati A: MicroRNAs as markers of
progression in cervical cancer: A systematic review. BMC Cancer.
18:6962018. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Laengsri V, Kerdpin U, Plabplueng C,
Treeratanapiboon L and Nuchnoi P: Cervical cancer markers:
Epigenetics and microRNAs. Lab Med. 49:97–111. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wang F, Li B and Xie X: The roles and
clinical significance of microRNAs in cervical cancer. Histol
Histopathol. 31:131–139. 2016.PubMed/NCBI
|
|
18
|
Granados-López AJ, Ruiz-Carrillo JL,
Servín-González LS, Martínez-Rodríguez JL, Reyes-Estrada CA,
Gutiérrez-Hernández R and López JA: Use of mature miRNA strand
selection in miRNAs families in cervical cancer development. Int J
Mol Sci. 18:E4072017. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Cui F, Li X, Zhu X, Huang L, Huang Y, Mao
C, Yan Q, Zhu J, Zhao W and Shi H: MiR-125b inhibits tumor growth
and promotes apoptosis of cervical cancer cells by targeting
phosphoinositide 3-kinase catalytic subunit delta. Cell Physiol
Biochem. 30:1310–1318. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zhu X, Er K, Mao C, Yan Q, Xu H, Zhang Y,
Zhu J, Cui F, Zhao W and Shi H: miR-203 suppresses tumor growth and
angiogenesis by targeting VEGFA in cervical cancer. Cell Physiol
Biochem. 32:64–73. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Granados López AJ and López JA: Multistep
model of cervical cancer: Participation of miRNAs and coding genes.
Int J Mol Sci. 15:15700–15733. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Wang YQ, Lu JL, Liang YR and Li QS:
Suppressive effects of EGCG on cervical cancer. Molecules.
23:E23342018. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Hou IC, Amarnani S, Chong MT and Bishayee
A: Green tea and the risk of gastric cancer: Epidemiological
evidence. World J Gastroenterol. 19:3713–3722. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Johnson R, Bryant S and Huntley AL: Green
tea and green tea catechin extracts: An overview of the clinical
evidence. Maturitas. 73:280–287. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Danese E, Minicozzi AM, Benati M, Paviati
E, Lima-Oliveira G, Gusella M, Pasini F, Salvagno GL, Montagnana M
and Lippi G: Reference miRNAs for colorectal cancer: Analysis and
verification of current data. Sci Rep. 7:84132017. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global Cancer Statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Ferlay J, Colombet M, Soerjomataram I,
Mathers C, Parkin DM, Piñeros M, Znaor A and Bray F: Estimating the
global cancer incidence and mortality in 2018: GLOBOCAN sources and
methods. Int J Cancer. 2018 Oct 23;Doi: 10.1002/ijc.31937.
View Article : Google Scholar
|
|
29
|
Quan Y and Yi Q: Across China: HPV vaccine
becomes available for women under 45 in Shanghai. xinhuanet.
03–Aug;2018.http://www.xinhuanet.com/english/2018-03/08/c_137025464.htm
|
|
30
|
Chen W, Zheng R, Baade PD, Zhang S, Zeng
H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in China,
2015. CA Cancer J Clin. 66:115–132. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Yang L, Zhu Y, Bai Y, Zhang X and Ren C:
The clinical application of HPV E6/E7 mRNA testing in triaging
women with atypical squamous cells of undetermined significance or
low-grade squamous intra-epithelial lesion Pap smear: A
meta-analysis. J Cancer Res Ther. 13:613–620. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Terenzi F, Saikia P and Sen GC:
Interferon-inducible protein P56, inhibits HPV DNA replication by
binding to the viral protein E1. EMBO J. 27:3311–3321. 2015.
View Article : Google Scholar
|
|
33
|
Shirakami Y and Shimizu M: Possible
mechanisms of green tea and its constituents against cancer.
Molecules. 23:E22842018. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Bettuzzi S, Brausi M, Rizzi F, Castagnetti
G, Peracchia G and Corti A: Chemoprevention of human prostate
cancer by oral administration of green tea catechins in volunteers
with high-grade prostate intraepithelial neoplasia: A preliminary
report from a one-year proof-of-principle study. Cancer Res.
66:1234–1240. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Lewinska A, Adamczyk-Grochala J,
Kwasniewicz E, Deregowska A and Wnuk M: Ursolic acid-mediated
changes in glycolytic pathway promote cytotoxic autophagy and
apoptosis in phenotypically different breast cancer cells.
Apoptosis. 22:800–815. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Wu L, Liu T, Xiao Y, Li X, Zhu Y, Zhao Y,
Bao J and Wu C: Polygonatum odoratum lectin induces apoptosis and
autophagy by regulation of microRNA-1290 and microRNA-15a-3p in
human lung adenocarcinoma A549 cells. Int J Biol Macromol.
85:217–226. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Kumar VB, Yuan TC, Liou JW, Yang CJ, Sung
PJ and Weng CF: Antroquinonol inhibits NSCLC proliferation by
altering PI3K/mTOR proteins and miRNA expression profiles. Mutat
Res. 707:42–52. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Zhou DH, Wang X and Feng Q: EGCG enhances
the efficacy of cisplatin by downregulating hsa-miR-98-5p in NSCLC
A549 cells. Nutr Cancer. 66:636–644. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Lorincz AT: Virtues and weaknesses of DNA
methylation as a test for cervical cancer prevention. Acta Cytol.
60:501–512. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Srivastava SK, Ahmad A, Zubair H, Miree O,
Singh S, Rocconi RP, Scalici J and Singh AP: MicroRNAs in
gynecological cancers: Small molecules with big implications.
Cancer Lett. 407:123–138. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Singh BN, Shankar S and Srivastava PK:
Green tea catechin, epigallocat-echin-3-gallate (EGCG): Mechanisms,
perspectives and clinical applications. Biochem Pharmacol.
82:1807–1821. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Wang F, Chang Z, Fan Q and Wang L:
Epigallocatechin 3 gallate inhibitsthe proliferation and migration
of human ovarian carcinoma cells by modulating p38 kinase and
matrix metalloproteinase-2. Mol Med Rep. 9:1085–1089. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Zhang D, Al-Hendy M, Richard-Davis G,
Montgomery-Rice V, Rajaratnam V and Al-Hendy A: Anti proliferative
and proapoptotic effects of epigallocatechin gallate on human
leiomyoma cells. Fertil Steril. 94:1887–1893. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Al-Hazzani AA and Alshatwi AA: Catechin
hydrate inhibits proliferation and mediates apoptosis of SiHa human
cervical cancer cells. Food Chem Toxicol. 49:3281–3286. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Hara-Terawaki A, Takagaki A, Kobayashi H
and Nanjo F: Inhibitory activity of catechin metabolites produced
by intestinal microbiota on proliferation of HeLa cells. Biol Pharm
Bull. 40:1331–1335. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Schetter AJ, Leung SY, Sohn JJ, Zanetti
KA, Bowman ED, Yanaihara N, Yuen ST, Chan TL, Kwong DL, Au GK, et
al: MicroRNA expression profiles associated with prognosis and
therapeutic outcome in colon adenocarcinoma. JAMA. 299:425–436.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Iorio MV, Visone R, Di Leva G, Donati V,
Petrocca F, Casalini P, Taccioli C, Volinia S, Liu CG, Alder H, et
al: MicroRNA signatures in human ovarian cancer. Cancer Res.
67:8699–8707. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Ladeiro Y, Couchy G, Balabaud C,
Bioulac-Sage P, Pelletier L, Rebouissou S and Zucman-Rossi J:
MicroRNA profiling in hepatocellular tumors is associated with
clinical features and oncogene/tumor suppressor gene mutations.
Hepatology. 47:1955–1963. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Gaur A, Jewell DA, Liang Y, Ridzon D,
Moore JH, Chen C, Ambros VR and Israel MA: Characterization of
microRNA expression levels and their biological correlates in human
cancer cell lines. Cancer Res. 67:2456–2468. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Craig VJ, Cogliatti SB, Rehrauer H,
Wündisch T and Müller A: Epigenetic silencing of microRNA-203
dysregulates ABL1 expression and drives Helicobacter-associated
gastric lymphomagenesis. Cancer Res. 71:3616–3624. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Banzhaf-Strathmann J and Edbauer D: Good
guy or bad guy: The opposing roles of microRNA 125b in cancer. Cell
Commun Signal. 12:302014. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Jiménez-Wences H, Peralta-Zaragoza O and
Fernández-Tilapa G: Human papilloma virus, DNA methylation and
microRNA expression in cervical cancer (Review). Oncol Rep.
31:2467–2476. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Hu G, Zhao X, Wang J, Lv L, Wang C, Feng
L, Shen L and Ren W: miR-125b regulates the drug-resistance of
breast cancer cells to doxorubicin by targeting HAX-1. Oncol Lett.
15:1621–1629. 2018.PubMed/NCBI
|
|
54
|
Yang D, Zhan M, Chen T, Chen W, Zhang Y,
Xu S, Yan J, Huang Q and Wang J: miR-125b-5p enhances chemotherapy
sensitivity to cisplatin by down-regulating Bcl-2 in gallbladder
cancer. Sci Rep. 7:431092017. View Article : Google Scholar : PubMed/NCBI
|
